- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03644303
Targeted Radiotherapy in Androgen-suppressed Prostate Cancer Patients. (TRAP)
TRAP - Targeted Radiotherapy in Androgen-suppressed Prostate Cancer Patients.
This multi-center, phase II trial will be conducted in men with castration resistant prostate cancer. The aim of the TRAP trial is to test whether a new precise radiotherapy technique called stereotactic body radiotherapy (SBRT) can slow down the growth of metastatic prostate cancer. If SBRT is effective it will represent a new treatment option in these patients, providing more prolonged control without having to resort to chemotherapy and its potentially unpleasant side effects.
In this trial, the investigators will identify men who, despite being on next generation androgen deprivation treatment (Abiraterone or Enzalutamide) have developed one or two new sites of worsening (growing) disease but the rest of their cancer is still responding to hormonal therapy. If it is the case that SBRT can successfully treat the cancer which is resistant to current treatment then the investigators hope they will be able to better control the spread of cancer in these patients for longer.
The investigators also hope that they will be able to use the tell-tale products (gene markers) that are released into the bloodstream in these patients, or identify characteristics on novel imaging such as magnetic resonance imaging (MRI) to help identify patients in the future who will benefit the most.
Study Overview
Status
Intervention / Treatment
Detailed Description
For many men with metastatic prostate cancer, the cancer develops resistance to successive systemic therapies and eventually all treatment options are exhausted and the patient succumbs to their disease. It is therefore vital to find ways of evading prostate cancer resistance. Stereotactic body radiotherapy (SBRT) has the advantage that it destroys cancerous tissue irrespective of the underlying genetic deficit within the progressing metastasis. If the resistant clones are localized to 1-2 metastases and can be destroyed or ablated, the patient can continue to receive the benefit of their systemic (androgen deprivation) treatment (Abiraterone or Enzalutamide) which may continue to control the remainder of their disease for many months, possibly even years.
SBRT is a recognised technique for the elimination of isolated metastases in other tumour sites achieving local control of metastasis in 80-90% of cases. This is achieved with very few side effects. In the TRAP trial, the investigators wish to establish whether it is beneficial to target 1 or 2 metastatic sites with SBRT or whether patients will develop polymetastatic progression. Patients enrolled on the trial will receive 30 Gy in 5 fractions on alternate days over 10 days. They will continue their androgen deprivation treatment throughout and following SBRT. Side effects will be closely monitored throughout and patients will be seen at the end of radiotherapy and then 4 weeks after treatment. Thereafter patients will undergo trial follow up three monthly which will includes Prostate Specific Antigen (PSA) monitoring.
In addition to the above procedures, the investigators will use a combination of whole body (WB) diffusion weighted (DW) magnetic resonance imaging (WB DW MRI) and circulating tumour (ct) deoxyribonucleic acid (DNA), 'ct DNA' biomarker analysis with the aim of identifying those patients which benefit most from the combination of SBRT and androgen deprivation treatment. WB DW MRI is a novel MRI technique which shows improved sensitivity compared to standard MRI. The marker ctDNA enables the investigators to explore genomic characterisation and variation of metastases and compare findings with previously explored genome mutations in prostate cancer patients.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Linda Wedlake, PhD
- Phone Number: +44 208 915 6767
- Email: linda.wedlake@rmh.nhs.uk
Study Contact Backup
- Name: Victoria Pittordou, BSc
- Phone Number: + 44 208 915 6766
- Email: victorai.pittordou@rmh.nhs.uk
Study Locations
-
-
Manchester Greater
-
Manchester, Manchester Greater, United Kingdom, M20 4BX
- Not yet recruiting
- The Christie NHS Foundation Trust
-
Contact:
- Ananya Choudhury, PhD
-
-
Northern Ireland
-
Belfast, Northern Ireland, United Kingdom, BT8 8BH
- Not yet recruiting
- Belfast Health & Social Care Trust
-
Contact:
- Suneil Jain
-
-
Surrey
-
Sutton, Surrey, United Kingdom, SM5 3EZ
- Recruiting
- The Royal Marsden NHS Foundation Trust
-
Contact:
- L J Wedlake, PhD
- Phone Number: 2089156767
- Email: linda.wedlake@rmh.nhs.uk
-
Contact:
- V J Pittordou, BSc
- Phone Number: 02089156766
- Email: victoria.pittordou@rmh.nhs.uk
-
Principal Investigator:
- Alison Tree, FRCR
-
Sub-Investigator:
- Gerhardt Attard, PhD
-
Sub-Investigator:
- NIna Tunariu, PhD
-
Sub-Investigator:
- Nicholas VanAs, MBBS
-
-
Tyne And Wear
-
Newcastle Upon Tyne, Tyne And Wear, United Kingdom, NE7 7DN
- Not yet recruiting
- The Newcastle upon Tyne Hospitals NHS Foundation Trust
-
Contact:
- John Frew, MBBS
-
-
Wales
-
Cardiff, Wales, United Kingdom, CF14 2TL
- Not yet recruiting
- Velindre Cancer Centre
-
Contact:
- John Staffurth, MBBS
-
-
West Midlands
-
Birmingham, West Midlands, United Kingdom, B15 2TH
- Not yet recruiting
- University Hospitals Birmingham NHS Foundation Trust
-
Contact:
- Daniel Ford, MBBS
-
-
West Yorkshire
-
Leeds, West Yorkshire, United Kingdom, LS9 7TF
- Not yet recruiting
- Leeds Teaching Hospitals NHS Trust
-
Contact:
- Ann Henry, PhD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Be willing and able to provide written informed consent for the trial and be ≥18 years of age on day of signing informed consent.
- Have metastatic Castration Resistant Prostate Cancer (CRPC) based on biochemical or pathological diagnosis and be on Enzalutamide or Abiraterone.
- Have had a minimum of 6 months on Enzalutamide or Abiraterone with evidence of response (PSA, radiological or symptomatic)
- Have 1 - 2 metastatic lesions progressing on imaging (CT, bone scan, MRI or other local imaging) or a clinical or imaging diagnosis of progression of a non-irradiated primary site with the remainder of their metastases currently controlled by Enzalutamide or Abiraterone.
- Have had no previous radical radiation to the index area (defined as unable to deliver SBRT doses in this protocol without taking normal tissues beyond tolerance).
- Have a Performance Status (PS) assessed using the Eastern Co-operative Oncology Group (ECOG) criteria of 0 - 1.
- Have an oligoprogressing site, including those that have developed on treatment, in bone, lymph node, prostate or lung but not in liver, brain, adrenal or other sites.
- Patients may be symptomatic in the oligoprogressing area. However, there is no urgent need to start radiotherapy.
Exclusion Criteria:
- A clinical need exists to switch therapy immediately (e.g. suspicion of rapid clinical progression, urgent need for palliative radiotherapy).
- Evidence of previous invasive cancer in the last 5 years, with the exception of non-melanoma skin cancer (non-invasive malignancies such as non-muscle invasive bladder cancer are not excluded).
- There is a contra-indication to radiotherapy (e.g. inflammatory bowel disease).
- There is a contra-indication to MRI where required for radiotherapy (e.g. cardiac pacemaker, internal defibrillator, shrapnel injury or claustrophobia).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: SBRT + ADT
Enzalutamide OR Abiraterone at licensed doses in combination with stereotactic radiotherapy: 30 Gray in 5 fractions
|
Short course SBRT to 1 or 2 oligo-progressing metastases in addition to continued abiraterone or enzalutamide
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Median Progression-Free Survival (PFS)
Time Frame: Outcome to be assessed at 6 months from end of SBRT
|
Median progression free survival following SBRT to oligo-progressing metastatic sites assessed using the RECIST (v 1.1) criteria on imaging such as computed Tomography (CT),bone scan, magnetic Resonance Imaging (MRI) or Positron Emission Tomography (PET) scan
|
Outcome to be assessed at 6 months from end of SBRT
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Local control rate following SBRT
Time Frame: Outcome to be assessed at 6 months and 1 year from end of SBRT
|
Overall control defined as stable disease or partial response of irradiated metastases assessed using the RECIST (v 1.1) criteria on imaging such as computed Tomography (CT), magnetic Resonance Imaging (MRI) or Positron Emission Tomography (PET) scan or control on bone scan
|
Outcome to be assessed at 6 months and 1 year from end of SBRT
|
Incidence and severity of treatment induced symptoms
Time Frame: From the start of SBRT up to 24 months following delivery of SBRT
|
Incidence of acute and late side-effects resulting from SBRT assessed using the Common Terminology Criteria for Adverse Events (CTCAE) and the Radiotherapy and Oncology Group Terminology Criteria for Adverse Events (CTCAE) and the RTOG (Radiotherapy Oncology Group) scoring criteria
|
From the start of SBRT up to 24 months following delivery of SBRT
|
Health Related Quality of Life
Time Frame: Change from start of radiotherapy to each time-point including 3 and 6 months after end of SBRT
|
Patient Reported Quality of Life assessed using the Euroqual (EQ) EQ-5D-5L questionnaire
|
Change from start of radiotherapy to each time-point including 3 and 6 months after end of SBRT
|
Time to administration of next line of therapy
Time Frame: From the end of SBRT up to 24 months following delivery of SBRT
|
Survival and median survival prior to alternative therapy administration
|
From the end of SBRT up to 24 months following delivery of SBRT
|
Association between selected WB DW MRI characteristics at baseline and prognosis after SBRT
Time Frame: Outcome to be assessed at 6 months and 1 year from end of SBRT
|
Correlation or regression analysis of characteristics (e.g.
number of metastases)
|
Outcome to be assessed at 6 months and 1 year from end of SBRT
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Exploration of novel bio-markers to assess response to SBRT treatment
Time Frame: Assessment of Progression Free Survival at 6 months and 1 year
|
Levels of circulating tumor Deoxyribonucleic Acid (ctDNA)
|
Assessment of Progression Free Survival at 6 months and 1 year
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Alison Tree, FRCR, Royal Marsden NHS Foundation Trust
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CCR 4781
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Prostate Cancer
-
Roswell Park Cancer InstituteRecruitingObesity | Overweight | Cancer Survivor | Prostate Adenocarcinoma | Stage I Prostate Cancer | Stage II Prostate Cancer | Stage III Prostate Cancer | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate Cancer | Stage IVA Prostate Cancer | Stage IVB Prostate Cancer | Stage A Prostate Cancer | Stage... and other conditionsUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Regeneron Pharmaceuticals; Prostate Cancer FoundationWithdrawnStage III Prostate Cancer | Stage IV Prostate Cancer | Stage IVA Prostate Cancer | Stage IVB Prostate Cancer | Stage IIIA Prostate Cancer | Stage IIIB Prostate Cancer | Stage IIIC Prostate Cancer
-
Jonsson Comprehensive Cancer CenterProgenics Pharmaceuticals, Inc.TerminatedRandomized Trial of PSMA PET Scan Before Definitive Radiation Therapy for Prostate Cancer (PSMA-dRT)Stage II Prostate Cancer AJCC v8 | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IIA Prostate Cancer AJCC v8 | Stage IIB Prostate Cancer AJCC v8 | Stage I Prostate...United States
-
University of Southern CaliforniaNational Cancer Institute (NCI); SanofiTerminatedDiarrhea | Recurrent Prostate Cancer | Hormone-resistant Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
Jonsson Comprehensive Cancer CenterNational Cancer Institute (NCI)CompletedRecurrent Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
Ryan Kohlbrenner, MDRadiological Society of North AmericaCompletedProstate Adenocarcinoma | Stage IV Prostate Cancer AJCC v8 | Prostate Carcinoma | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer AJCC v8 | Stage...United States
-
Mayo ClinicNational Cancer Institute (NCI)WithdrawnStage I Prostate Cancer AJCC v8 | Stage II Prostate Cancer AJCC v8 | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IIA Prostate Cancer AJCC v8 | Stage IIB Prostate...United States
-
Barbara Ann Karmanos Cancer InstituteGenentech, Inc.CompletedRecurrent Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Adenocarcinoma of the Prostate | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
Ohio State University Comprehensive Cancer CenterRiverside Methodist HospitalCompletedStage I Prostate Cancer | Stage III Prostate Cancer | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
University of California, IrvineCompletedRecurrent Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Adenocarcinoma of the Prostate | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
Clinical Trials on SBRT + ADT
-
Changhai HospitalRecruiting
-
University Health Network, TorontoAstellas Pharma IncRecruitingMetastatic Prostate CancerCanada
-
European Institute of OncologyRecruitingOligometastatic Prostate CancerItaly
-
VA Greater Los Angeles Healthcare SystemActive, not recruiting
-
Otsuka Pharmaceutical Development & Commercialization...CompletedMental Disorders | Depressive Disorder | Depression | Mood Disorders | Depressive Disorder, MajorUnited States, Russian Federation, Hungary, Romania, Ukraine, Canada, Germany
-
Changhai HospitalRecruiting
-
Weill Medical College of Cornell UniversityConvergent Therapeutics, Inc.WithdrawnProstate Cancer MetastaticUnited States
-
Peking University First HospitalThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical... and other collaboratorsRecruiting
-
Otsuka Pharmaceutical Development & Commercialization...CompletedMental Disorders | Depressive Disorder | Depression | Mood Disorders | Depressive Disorder, MajorUnited States, France, Poland, Canada, Slovakia
-
Peter Busch ØstergrenRecruitingProstate Cancer MetastaticDenmark